Shopping Cart
Remove All
Your shopping cart is currently empty
Atebimetinib (IMM-1-104) is an orally active, deeply periodic MEK inhibitor that directly targets MEK and chronically suppresses MAPK signaling. It is intended for combination therapy in metastatic pancreatic cancer and non-small cell lung cancer (NSCLC).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $239 | - | In Stock | |
| 5 mg | $596 | - | In Stock | |
| 10 mg | $953 | - | In Stock | |
| 25 mg | $1,880 | - | In Stock | |
| 50 mg | $2,970 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $663 | - | In Stock |
| Description | Atebimetinib (IMM-1-104) is an orally active, deeply periodic MEK inhibitor that directly targets MEK and chronically suppresses MAPK signaling. It is intended for combination therapy in metastatic pancreatic cancer and non-small cell lung cancer (NSCLC). |
| Molecular Weight | 506.55 |
| Formula | C23H27FN4O6S |
| Cas No. | 2669009-92-9 |
| Smiles | O=C1OC=2C=C(OC(=O)N(C)C)C=CC2C(=C1CC=3C=CC=C(NS(=O)(=O)NC)C3F)CN(C)C |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80.00 mg/mL (157.93 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.